As the rollout of three authorized vaccines continues here in the US, other drugmakers are still carrying on in their pursuits to arm the world with more effective shots.
The companies are now looking at approval by the end of 2021.
Meanwhile, Novavax, which is close to getting the green light from the Food and Drug Administration for its coronavirus vaccine, still faces a key challenge.
It's a case of a well-funded startup (Ro) acquiring a smaller company (Modern Fertility) to keep growing.
And Ro isn't the only one acquiring. Cedar last week said it's buying rival Ooda Health, and Grand Rounds in March said that it's buying telehealth startup Dr. On Demand.
We're calling it the start of a "consolidation tsunami."
Speaking of acquisitions - health insurer Bright Health filed to go public on Wednesday, and its filings provided our best look yet at how the company is growing.
Of the five health insurance startups we've been tracking for the past few years-Alignment, Bright, Clover, Devoted, and Oscar-there's only one left that hasn't started the going-public process (as far as we know): Devoted Health.
We'll still be looking over insurance filings to see how Devoted is doing.
